ATE316524T1 - Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität - Google Patents

Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität

Info

Publication number
ATE316524T1
ATE316524T1 AT01905903T AT01905903T ATE316524T1 AT E316524 T1 ATE316524 T1 AT E316524T1 AT 01905903 T AT01905903 T AT 01905903T AT 01905903 T AT01905903 T AT 01905903T AT E316524 T1 ATE316524 T1 AT E316524T1
Authority
AT
Austria
Prior art keywords
substituted
unsubstituted
oxy
derivatives
amino
Prior art date
Application number
AT01905903T
Other languages
English (en)
Inventor
Tatsuo Higa
Junichi Tanaka
Gravalos Dolores Garcia
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0003629A external-priority patent/GB0003629D0/en
Priority claimed from GB0021774A external-priority patent/GB0021774D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE316524T1 publication Critical patent/ATE316524T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01905903T 2000-02-16 2001-02-16 Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität ATE316524T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0003629A GB0003629D0 (en) 2000-02-16 2000-02-16 Antitumour agent
GB0021774A GB0021774D0 (en) 2000-09-05 2000-09-05 Anti-tumour compound

Publications (1)

Publication Number Publication Date
ATE316524T1 true ATE316524T1 (de) 2006-02-15

Family

ID=26243662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01905903T ATE316524T1 (de) 2000-02-16 2001-02-16 Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität

Country Status (17)

Country Link
US (1) US6864283B2 (de)
EP (1) EP1255746B1 (de)
JP (1) JP2003523338A (de)
KR (1) KR20020092958A (de)
CN (1) CN1318409C (de)
AT (1) ATE316524T1 (de)
AU (2) AU2001233873B2 (de)
BR (1) BR0108448A (de)
CA (1) CA2400612C (de)
CZ (1) CZ20022791A3 (de)
DE (1) DE60116855T2 (de)
ES (1) ES2256199T3 (de)
IL (1) IL151241A (de)
MX (1) MXPA02007995A (de)
PL (1) PL357193A1 (de)
RU (1) RU2002124591A (de)
WO (1) WO2001060810A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1318409C (zh) 2000-02-16 2007-05-30 法马马有限公司 具有抗肿瘤活性的氧基-和氨基-取代的四氢呋喃基衍生物
CN102229585A (zh) * 2011-04-26 2011-11-02 中国人民解放军第二军医大学 具有抗肿瘤活性的γ-丁内酯聚酮类化合物
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US6107520A (en) * 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
CN1318409C (zh) 2000-02-16 2007-05-30 法马马有限公司 具有抗肿瘤活性的氧基-和氨基-取代的四氢呋喃基衍生物

Also Published As

Publication number Publication date
CN1423642A (zh) 2003-06-11
KR20020092958A (ko) 2002-12-12
CA2400612C (en) 2010-05-11
PL357193A1 (en) 2004-07-26
CN1318409C (zh) 2007-05-30
EP1255746B1 (de) 2006-01-25
WO2001060810B1 (en) 2001-11-29
US20030092738A1 (en) 2003-05-15
US6864283B2 (en) 2005-03-08
CZ20022791A3 (cs) 2003-02-12
WO2001060810A1 (en) 2001-08-23
IL151241A (en) 2006-10-31
BR0108448A (pt) 2003-04-01
RU2002124591A (ru) 2004-01-10
MXPA02007995A (es) 2003-05-23
EP1255746A1 (de) 2002-11-13
AU3387301A (en) 2001-08-27
JP2003523338A (ja) 2003-08-05
DE60116855D1 (de) 2006-04-13
ES2256199T3 (es) 2006-07-16
DE60116855T2 (de) 2006-09-14
CA2400612A1 (en) 2001-08-23
AU2001233873B2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
ATE253051T1 (de) Chinolinderivate und chinazolinderivate
MXPA04001240A (es) Analogos antitumorales.
ATE180468T1 (de) Anthranilsäure derivate
FR18C1006I2 (fr) Derives de quinoline ayant un groupe azolyle et derives de quinazoline
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
ATE303063T1 (de) Synthetische analoge des ecteinascidin-743
ES2166954T3 (es) Derivados de 1-fenilpirazol y su uso como agentes parasiticidas.
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
ATE513821T1 (de) Thiadiazolin-derivate zur behandlung von krebs
ATE316524T1 (de) Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität
EP1056700A4 (de) Medizinische anwendungen von phenylalkanolen und derivaten davon
ATE480533T1 (de) Variolinderivate und ihre verwendung als cytostatika
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
ITMI912421A1 (it) Derivati eterociclici di alcossiacrilati ad attivita' fungicida
NO20051037L (no) Totalsyntese av myriaporoner
ATE311182T1 (de) Benzopyranderivate zur behandlung von perihperer gefässerkrankung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties